Results of phase III STAR trial for MS pseudobulbar affect

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Results of phase III STAR trial for MS pseudobulbar affect

Postby MSUK » Thu Sep 16, 2010 1:02 am

Image

Avanir Pharmaceuticals, Inc. announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology.

The publication entitled "Dextromethorphan Plus Ultra-Low-Dose Quinidine Reduces Pseudobulbar Affect" evaluated two low dose formulations compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).

PBA is a neurologic condition characterized by involuntary, unpredictable and disruptive outbursts of laughing or crying in patients with certain underlying neurologic diseases or injuries....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2882
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2088
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users